about
The Global HIV/AIDS Vaccine Enterprise: scientific strategic planHow do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked?Antibody responses to envelope glycoproteins in HIV-1 infectionAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinImmune-correlates analysis of an HIV-1 vaccine efficacy trialHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesComparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10The cat and mouse of HIV-1 antibody escape.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women.Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesB cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesIn vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.Structure-based vaccine design in HIV: blind men and the elephant?Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesSelection on the human immunodeficiency virus type 1 proteome following primary infection.Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.Stoichiometry of murine leukemia virus envelope protein-mediated fusion and its neutralization.Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus InfectionThe role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralizationEfficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsAPOBEC3G levels predict rates of progression to AIDSCorrelates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.
P2860
Q21563445-F8E1EFE0-4B5C-4368-A4C9-9F9450AAD1D4Q25257230-36593504-D052-4A56-820E-5AD1D576705BQ26991572-1A2B3354-91F9-4128-B329-494395237114Q27489000-B9CF7786-E9B0-4CA5-B9A6-20544A5C7A15Q28743092-72E97EDC-1C7A-4A6F-9D21-D7B2B82ECE0FQ29617377-F96371A9-49C1-42CD-9E2A-2304161DD1FCQ29619015-2B2E5F94-2F99-4044-85A5-CCB3C9255B84Q30360326-9BC229F4-D74E-4CBC-9AD5-D60601FD542DQ33272711-3F3E1C52-4995-4AF9-9157-8EAB42F75A00Q33504607-DE71B1AF-6C39-47F5-B296-B25171B1C399Q33571825-C4FB029C-F8DC-47EB-A1FA-5E60A501111CQ33624872-49C127B5-9D3A-4D5B-B2E3-46D7E488F0D9Q33667654-2C41E83E-E9EA-4483-A45C-068A5B24F5B0Q33719511-88A40FDF-6566-4409-A10C-18E53C3341C8Q33911935-2CC0059E-FEA9-4C0E-9ED7-F64E8C3283F6Q34008741-2DFA702E-A090-4F31-AC77-E774CAD5D4E6Q34047445-7959DC4A-5D6D-4E1C-8875-1EC2B2DEB963Q34096475-B17A0853-641F-4281-ACDE-65673645AA57Q34117097-4BD8F94D-4944-44C7-BDA3-6D90CA718636Q34150125-D0A32CA3-DE59-4095-A0A1-A7FC05B17EE3Q34324992-5230A1DB-F079-48CD-9B8D-8313562E8855Q34974016-77C252C3-EDFE-443A-B3C4-4462CD3D9CF1Q34987048-998EFD26-A3BA-4A22-B1C4-AAB8F01DEEF9Q34999724-77EC0F74-2715-4918-B00F-8F83C3846B37Q35101333-1A34EC2F-03C1-45ED-9AD7-1C0C497B3E5BQ35101338-49C3BAAC-0AEC-431B-B6C1-D57CF3565C59Q35123128-CCD0E5FB-EA3A-4952-A83A-4FD1D0499C99Q35140032-2177C0F2-04B0-4942-B77A-28867A2582A5Q35185954-29176854-337B-458D-8248-A85A4C68AE5CQ35208657-E99F909E-A8CC-47DF-ACF3-229B1B9BA04CQ35580892-85A0B993-9D8C-4F0A-84AE-CD979AA16783Q35603504-4D755F07-3565-4D19-9034-3F9F9CF678CEQ35641234-BE148042-109B-49AF-BD49-46279328D25BQ35644971-A749FF78-5192-43EA-9D2A-ADE984B67398Q35677724-A75FA6FB-E731-4FE7-BD57-4E8F9FA1ECE8Q35699707-B02F2217-9206-4024-AA5D-B8773F8656A0Q35852348-5895B50B-8B0F-4037-9930-89FEE7DFEEAAQ35914292-20A1D9C4-8650-4806-B236-D4446A2BD4B2Q36009232-0FF634D9-2615-49A1-9301-55FBDE4D7EC5Q36141610-FD61FB56-92D5-4C55-9D37-A4F38EE4DF89
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Defining the protective antibody response for HIV-1.
@ast
Defining the protective antibody response for HIV-1.
@en
type
label
Defining the protective antibody response for HIV-1.
@ast
Defining the protective antibody response for HIV-1.
@en
prefLabel
Defining the protective antibody response for HIV-1.
@ast
Defining the protective antibody response for HIV-1.
@en
P356
P1476
Defining the protective antibody response for HIV-1.
@en
P304
P356
10.2174/1566524033479799
P577
2003-05-01T00:00:00Z